Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

What is CoinBharat? Financial Guide to Success

By Jagat Joshi
December 28, 2022

The global economy is changing irreversibly. Financial markets are being disrupted by cutting-edge technology that even the most established players were not prepared for while India rises to become a global economy with a powerful middle class. As more and more Indians enter the middle class, the more important financial education becomes to make sure that those without a background in finance and wealth management can protect their hard-earned money from a high-inflation environment. Towards that goal, CoinBharat is here to help.

CoinBharatis a platform founded by Indian ex-pats living in the US to empower everyday Indians back home to follow in their footsteps by making sound strategic investments. CoinBharat is India’s first community-driven educational platform for all finance matters. CoinBharat offers a wide array of educational tools that cover asset classes from stocks to NFTs that new and seasoned stock investors could use to maximize profits. In this post(article), we will be talking about CoinBharat, how to buy stocks in India, and how the future can be brighter for the burgeoning Indian middle class if they heed some critically important financial advice.

What is CoinBharat?

CoinBharatis your go-to source for financial information about all the things that have to do with investments, with several informative articles and a website designed to increase your general understanding of the subjects.

The day when only well-known financial industry figures, such as Mark Cuban, Shivon Zilis, and Kevin O’Leary, was knowledgeable about personal wealth over. The market is now more accessible and open to everyone looking to move.

CoinBharatwas established by a group of Indian ex-pats who had a specific goal and, to that end, solicited the aid of knowledgeable Indian investors to fix the knowledge gap in the region.

The website aims to inform the general public on blockchain technology, cryptocurrencies, NFTs, Stock, and other topics they might not be familiar with but that are extremely important for the growth of personal wealth and the acquisition of financial freedom.

In an era where inflation is pervasive, con artists are everywhere, and the global markets are in disarray, CoinBharat seeks to be a compass and guide for seasoned investors and rookie traders determined to achieve financial independence.

When it comes to the pervasive issue of news and information about cryptocurrencies being incredibly biased, Coinbharat offers a breath of fresh air because the information it provides its readers with is always based on the findings and research of some of the top investors and is impartial, unbiased, and generally trustworthy advice for anyone to follow as they navigate the world of cryptocurrencies.

The Mission of Coinbharat

Through the power of the internet and the access it grants retail investors to assets like stocks, ETFs, crypto, and NFTs, the typical Indian today has access to many ways to acquire, grow, and keep his wealth. When done appropriately and ethically, the capacity to buy, own, and trade these assets has generated enormous wealth. This has been achieved using traditional strategies like trend analysis and cutting-edge strategies like trading powered by artificial intelligence. The Great Financial Crash of 2008 is a testament to why we do not feel that the capacity to survive inflation and prosper in any economic situation should be isolated and kept in the hands of a privileged elite of market manipulators.

The CoinBharat team set out to develop an investment toolkit and guide in order to assist India’s expanding middle class in making the best use of their hard-earned riches by harnessing the power of financial literacy. With the digitization of the Indian economy and the country’s expanding number of entrepreneurs, business owners, financial specialists, and retail investors, this is the ideal time to create the groundwork for a financially educated populace to lead the nation’s future.

What is the stock market?

By definition, the stock market is the economic institution where public transactions for buying and selling securities are carried out. Closer to home, “it is where companies break up, and people can buy a minority part of them and participate in their profit and growth.”

How to Buy Stocks in India?

If you want to buy shares, you must first speak with a member or broker of a stock exchange registered with SEBI. However, in the modern day, you can also use a stock trading bot with which you don’t have to put much effort into trading. Furthermore, you can make your Trading account using online brokerage platforms. You must first register as an investor by doing the following things before you can begin investing:

Find a Registered Member/Broker of SEBI
Classify the stock exchange with which they are enumerated. The majority of agents are members of both exchanges.
Obtain your Aadhar card, passport, passbook, and other related documents
Submit the KYC and Agreement forms, and request copies
Open your DEMAT account and deposit the required amounts and start investing!

Why invest in the Stock Market?

There are many investments such as; the stock market, real estate, precious metals, fine art, etc., and none are perfect assets in every market condition. They all have their advantages and disadvantages and no investment is better than the others in all respects. The good thing is that all investments are compatible, so you don’t have to choose just one of them and give up all the others. The investments that each investor chooses and the percentage of his money that he dedicates to each of them are decided through said investor’s particular approach to wealth management.

Investing in the stock market is much easier than most people think since anyone can and should do without prior knowledge or above-average intelligence. CoinBharat believes that everyone should dedicate at least part of their money towards investing in the stock market since it has been shown that it is the most profitable investment in the long term. And not only is it the most beneficial, but through dividends, it provides a more stable and growing income than real estate or fixed income. It is also highly recommended to have a part of the money in fixed income, which is equally compatible with real estate investment. The stock market has security, profitability, liquidity, and flexibility far superior to any other type of asset.

Conclusion:

To summarise, CoinBharat plans to tackle the knowledge gap experienced by the growing Indian middle class through financial education and value-based community action. One of their main pillars is the stock market, which they point out is a vital tool to diversify a good portfolio and ensure that even the average person can grow their own wealth. If you want to read more informative articles, keep visiting our website.

Follow IPO Watch for the upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.